Skip to main content
AZ's hairy cell leukemia drug approved by FDA

AstraZeneca's orphan drug-tagged Lumoxiti, or moxetumomab pasudotox-tdfk, injection was approved by the FDA to treat adult patients with relapsed or refractory hairy cell leukemia who had two or more prior lines of purine nucleoside analog or other systemic treatment.

Full Story: